Randomized Trial of Paclitaxel Versus Pegylated Liposomal Doxorubicin for Advanced Human Immunodeficiency Virus-Associated Kaposi Sarcoma: Evidence of Symptom Palliation From Chemotherapy

Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom p...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2010-08, Vol.116 (16), p.3969-3977
Main Authors: CIANFROCCA, Mary, LEE, Sandra, VON ROENN, Jamie, TULPULE, Anil, DEZUBE, Bruce J, ABOULAFIA, David M, AMBINDER, Richard F, LEE, Jeannette Y, KROWN, Susan E, SPARANO, Joseph A
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antiretroviral Therapy, Highly Active
Biological and medical sciences
Dermatology
Disease-Free Survival
Doxorubicin - administration & dosage
Doxorubicin - analogs & derivatives
Early Termination of Clinical Trials
Female
HIV Infections - complications
Humans
Male
Medical sciences
Middle Aged
Paclitaxel - administration & dosage
Polyethylene Glycols - administration & dosage
Quality of Life
Sarcoma, Kaposi - drug therapy
Sarcoma, Kaposi - mortality
Sarcoma, Kaposi - psychology
Sarcoma, Kaposi - virology
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Paclitaxel and pegylated liposomal doxorubicin (PLD) are active cytotoxic agents for the treatment of human immunodeficiency virus (HIV)-associated Kaposi sarcoma (KS). A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined. Patients with advanced HIV-associated KS were randomly assigned to receive paclitaxel at a dose of 100 mg/m2 intravenously (iv) every 2 weeks or PLD at a dose of 20 mg/m2 iv every 3 weeks. The KS Functional Assessment of HIV (FAHI) quality of life instrument was used before and after every other treatment cycle. The study included 73 analyzable patients enrolled between 1998 and 2002, including 36 in the paclitaxel arm and 37 in the PLD arm; 73% of patients received highly active antiretroviral therapy (HAART) and 32% had an undetectable viral load (
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.25362